Campral review

Campral, also known by the generic name of acamprosate, is a medicine used to treat alcohol dependence. It is believed to stabilize the chemical imbalance in the brain caused by frequent alcohol intake or alcoholism, most probably by activating gamma-aminobutyric acid (GABA) Type A receptors and blocking glutaminergic N-methyl-D-aspartate receptors.

It is sold as white and odorless 333 milligram tablets of acamprosate calcium, which is the equivalent of 300 milligrams of acamprosate. Forest Laboratories is the manufacturer and distributor of Campral in the United States, while Merck KGaA is the one who markets the drug outside the US.

The typically suggested dose of Campral is two 333 milligram tablets—or a total of 666 milligrams per dose—taken three times every day. Even though dosing may be accomplished without regard to food or liquid intake, dosing with meals was usually employed during clinical trials of the medication and it is suggested as an aid in accordance to those patients who regularly eat three meals a day.

In addition, a lowered dose is reported to be effective is several patients as well. Campral treatment should be performed as quickly as the patient has undergone a period of alcohol withdrawal—that is, when he has achieved alcohol abstinence by himself—and should be maintained if he ever relapses.

This drug should not be taken by people allergic to the drug and who have kidney problems. Patients with moderate renal impairment—creatinine clearance of 30 to 50 mL/min—should have their Campral dose reduced. A starting dose of one 333 milligram tablet taken three times every day is advised for such patients. As for those with severe renal impairment—creatinine clearance of more than 30 mL/min—should not be given Campral altogether.

Campral should be used as part of an all-inclusive psychosocial treatment program as opposed to being used as a standalone, curative drug. That is to say, Campral should go hand-in-hand with alcohol rehabilitation. In fact, there have been reports that Campral best works with a combination of disciplined abstinence from alcohol and regular attendance to support groups.

In the controlled clinical trials used to evaluate Campral's benefits and disadvantages, reports of suicidal tendencies and ideation, suicide attempts, and completed suicides were rare overall, but were more common in Campral-treated patients than in patients treated with placebos. There were about 1.4% versus 0.5% in studies of six months or less and 2.4% versus 0.8% in annual studies. Successful suicides happened in 3 of every 2,272 patients or 0.13% in the combined Campral-treated group from all controlled studies, while 2 out of 1,962 patients or 0.10% in the placebo-treated group. Instances of depression were reported at similar rates in both groups.

Even though many of the above circumstances occurred in the context of alcohol relapse, a consistent pattern of relationship between the emergence of suicidal tendencies and the clinical course of recovery from alcoholism has yet to be identified. The connection between alcohol dependence, depression, and feelings of suicide are well-recognized and complex, such that there are too many outside factors to consider before coming up with a viable conclusion in regards to this complicated relationship.

For the body as a whole, the most common side effects are suicidal tendencies and suicide attempts, chills, chest pain, flu symptoms, infection, back pain, abdominal pain, and headache. Occasional side effects include intentional self injury, hernia, neck pain, abscess, allergic reaction, malaise, intentional overdose, and fever.

For the cardiovascular system, the most common side effects include syncope and palpitation, while occasional side effects include tachycardia, hemorrhage, phlebitis, myocardial infarct, varicose veins, angina pectoris, hypotension, and postural hypotension.

For the digestive system, the most common side effects are increased appetite, constipation, dyspepsia, and vomiting, while occasional side effects are hepatitis, nausea, vomiting, hematemesis, esophagitis, liver cirrhosis, rectal hemorrhage, gastrointestinal hemorrhage, eructation, dysphagia, gastritis, gastroenteritis, and abnormal liver function.

Campral has the following structural formula:

Chemical structure of campral

• Molecular formula of campral is C5H11NO4S
• Chemical IUPAC Name is 3-acetylaminopropane-1-sulfonic acid
• Molecular weight is 181.211 g/mol
Campral available : 300mg tablets

Generic name: Acamprosate

Brand name(s): Acamprosato, Acamprosatum, Aotal

  Your Campral review